Medical cannabis developer GW Pharma close to final breakthrough

0
81

May 29 2018, 12:01am, The Times Twenty years after the Home Office issued a biotechnology start-up with a licence to grow cannabis in southern England, GW Pharmaceuticals is set to launch a potential blockbuster drug. The British-based, Nasdaq-listed drugs company is hoping to receive approval from the US Food and Drug Administration next month for Epidiolex, a cannabis-based treatment for severe childhood epilepsy. If it is successful, GW is hoping to launch the medicine in Britain and Europe next year. Justin Gover, chief executive, said that approval would bring recognition that cannabis research was “serious science” and “that this type of medicine and these classes of medicines could become important drugs across a range of other disease areas”. GW is developing a pipeline of cannabis-derived medicines targeting cancer and autism. Unlock quality journalism on the topics that you decide matter most. Medical cannabis developer GW Pharma close to final breakthrough

thumbnail courtesy of thetimes.co.uk

LEAVE A REPLY

Please enter your comment!
Please enter your name here